Trimodality Therapy in Bladder Cancer Who, What, and When?

被引:29
|
作者
Premo, Christopher [1 ]
Apolo, Andrea B. [2 ]
Agarwal, Piyush K. [3 ]
Citrin, Deborah E. [1 ]
机构
[1] NIH, Radiat Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA
[2] NCI, Bladder Canc Sect, Genitourinary Malignancies Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA
[3] NCI, Bladder Canc Sect, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
TRANSITIONAL-CELL-CARCINOMA; COMBINED-MODALITY THERAPY; LONG-TERM OUTCOMES; SELECTIVE ORGAN PRESERVATION; GROWTH-FACTOR RECEPTOR; QUALITY-OF-LIFE; RADIATION-THERAPY; TRANSURETHRAL RESECTION; RADICAL RADIOTHERAPY; NEOADJUVANT CHEMOTHERAPY;
D O I
10.1016/j.ucl.2015.02.002
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Radical cystectomy is a standard treatment of nonmetastatic, muscle-invasive bladder cancer. Treatment with trimodality therapy consisting of maximal transurethral resection of the bladder tumor followed by concurrent chemotherapy and radiation has emerged as a method to preserve the native bladder in highly motivated patients. Several factors can affect the likelihood of long-term bladder preservation after trimodality therapy and therefore should be taken into account when selecting patients. New radiation techniques such as intensity modulated radiation therapy and image-guided radiation therapy may decrease the toxicity of radiotherapy in this setting. Novel chemotherapy regimens may improve response rates and minimize toxicity.
引用
收藏
页码:169 / +
页数:13
相关论文
共 50 条
  • [1] Trimodality Therapy for Bladder Conservation in Treatment of Invasive Bladder Cancer
    Timur Mitin
    William U. Shipley
    Jason A. Efstathiou
    Niall M. Heney
    Donald S. Kaufman
    Richard J. Lee
    Anthony L. Zietman
    Current Urology Reports, 2013, 14 : 109 - 115
  • [2] Trimodality Therapy for Bladder Conservation in Treatment of Invasive Bladder Cancer
    Mitin, Timur
    Shipley, William U.
    Efstathiou, Jason A.
    Heney, Niall M.
    Kaufman, Donald S.
    Lee, Richard J.
    Zietman, Anthony L.
    CURRENT UROLOGY REPORTS, 2013, 14 (02) : 109 - 115
  • [3] Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer
    Johnson, Skyler B.
    Yu, James B.
    CURRENT ONCOLOGY REPORTS, 2018, 20 (09)
  • [4] Trimodality therapy for bladder preservation in the elderly population with invasive bladder cancer
    Turgeon, Guy-Anne
    Souhami, Luis
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [6] Neoadjuvant therapy for esophageal cancer: Who, when, and what?
    Greally, Megan
    Ilson, David H.
    CANCER, 2018, 124 (22) : 4276 - 4278
  • [7] Trimodality Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer
    Chen, Ronald C.
    Shipley, William U.
    Efstathiou, Jason A.
    Zietman, Anthony L.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (08): : 952 - 960
  • [8] Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer
    Skyler B. Johnson
    James B. Yu
    Current Oncology Reports, 2018, 20
  • [9] Trimodality therapy for bladder cancer: modern management and future directions
    Pham, Anthony
    Ballas, Leslie K.
    CURRENT OPINION IN UROLOGY, 2019, 29 (03) : 210 - 215
  • [10] Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder Cancer
    Singh, Parminder
    Ballas, Leslie
    Sonpavde, Guru P.
    Chen, Ronald C.
    Bangs, Rick
    Bauman, Brian C.
    Nagar, Himanshu
    Delacroix, Scott E.
    Lerner, Seth P.
    Efstathiou, Jason A.
    BLADDER CANCER, 2024, 10 (03) : 199 - 213